The following content is for informational purposes only. This article is not intended to be a substitute for profession

Eli Lilly, the makers of tirzepatide—which they sell as Mounjaro for diabetes and Zepbound for weight loss— announced recently that in its longest study yet on tirzepatide, the drug reduced the risk of people with prediabetes moving on to develop diabetes by 94% compared to those taking a placebo.

Injectable prescription drugs that reduce appetite — like Ozempic, Saxenda and Mounjaro — have skyrocketed in popularity in recent years. Now, Cleveland Clinic researchers may have figured out which patients have the best odds of success.

The controversy around Ozempic started when celebrities, including Elon Musk, publicly endorsed its use for weight loss, sparking debates over its efficacy and safety outside its primary diabetes management role.

Zmyra is a weight loss supplement that has shown proven results but is it better than ozempic? Find out here. Recently, I've observed an alarming trend in which many of us struggle in the midst of unwanted weight gain.